Shatalyuk S. Influence of the metabolic syndrome on the bening prostatic hyperplasia clinical course.

The thesis is devoted to the studying of metabolic syndrome (MS) influence on the benign prostatic hyperplasia (BPH) clinical course. The study is based on a retrospective analysis of 429 case records of men with BPH, and clinical ex-amination of 163 patients aged (65.6±7.7) years, and dynamic monitoring of 65 patients with BPH during a year. Metabolic syndrome was diagnosed by ATP (NHI) criteria. It's frequency was 37.1% according to the retrospective data. According to the clinical examination - 51.0%. The rate of MS had age fluctuations and had the greatest prevalence among patients above 74 years old - 65.6%, mature age (45-59 years) - 57,1%, in elderly males (60-74) - 47.8%. The analysis of BPH symptoms in patients with MS showed increased irritative symptoms, urodynamics deterioration, increasing BPH size comparing to uncomplicated MS patients. The concentration of total testosterone was lower in patients with MS an average by 31.9%. MS patients quality of life was in worse for all types of functioning. It was found out that BPH of patients with MS had its morphological fea-tures: more pronounced signs of atherosclerosis, chronic nonspecific inflammation, degenerative stroma changes.A carried out dynamic observation proved the accelerated rates of hypogonadism progression, BPH growth, deterioration of urodynamic and quality of life in MS complicated patients. Standard conservative treatment of BPH complicated with metabolic syndrome in combination with energotropic and anti-oxidant therapy during the year improved the average urine flow rate (on 11.8%), slowed down the total testosterone blood decreasing (on 17.6%), de-creased the concentration of uric acid on 11.0%.